Sandoz Group Ag reiterated earnings guidance for the full year 2024. For the year, The company reiterates guidance expecting net sales to grow mid-single digit in constant currencies versus prior year .
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
31.99 CHF | -0.87% | -1.72% | +18.22% |
May. 08 | AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents | MT |
May. 08 | AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+18.22% | 15.15B | |
+21.63% | 44.11B | |
+23.03% | 22.71B | |
+12.66% | 13.56B | |
+60.18% | 12.7B | |
-10.02% | 6.84B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+12.92% | 5.63B | |
+6.11% | 4.77B |
- Stock Market
- Equities
- SDZ Stock
- News Sandoz Group AG
- Sandoz Group Ag Reiterates Earnings Guidance for the Full Year 2024